Sofinnova

Nanobodies®, derived from natural single chain antibodies in Camelides, will be the next generation therapeutic antibodies. The anti-TNFalpha is the first under clinical investigation.

Alosteric modulation of m-gluR receptors is on the forefront of innovations for new CNS drugs and specifically for anxiety, depression and schizophrénia.

Movetis is a spin-off from Johnson & Johnson devoted to the development of drugs targeting gastrointestinal diseases.

Bioamber is a renewable chemistry company spun off from the US biotech company DNP Inc, and developping bio sourced molecules as alternatives to petroleum feedstock derived molecules for the chemical industry.

Diallertest® Milk is becoming the standard of diagnostic for young children milk allergy. DBV is developping this VIASKIN® technology to diagnose and treat other allergies like peanuts…

Omthera Pharmaceuticals is a cardiovascular specialty company developing a best in class Omega-3 pharmaceutical product called Epanova for the treatment of elevated triglyceredemia. Omthera owns a worldwide exclusive licence to Epanova.

Producing glyconjugates in a single step is the challenge GlycoVaxyn is facing in order to get vaccins cheaper and easier to produce.

Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries.

Percutaneous aortic valve replacement is a technology breakthrough for patients who will need only a few days of hospitalisation.

PregLem is a Swiss based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women’s reproductive medicine.